BAY 299 + SGC 3027 + SGC 0946

BAY 299 + SGC 3027 + SGC 0946 is a combination of small molecule epigenetic inhibitors targeting bromodomains and chromatin regulators. **BAY 299** (developed collaboratively by Bayer and the Structural Genomics Consortium) is a potent, selective inhibitor of the bromodomains in **TAF1** (transcription initiation factor TFIID subunit 1, IC50 8-13 nM for second bromodomain) and **BRD1**/**BRPF2** (bromodomain and PHD finger-containing protein 2, IC50 6-67 nM), disrupting their binding to histones H3.3 and H4 and showing >30-fold selectivity over related bromodomains like BRPF family members, BRD9, ATAD2, and >300-fold over BRD4; it induces cell death, cell cycle arrest, and differentiation in acute myeloid leukemia (AML) models via apoptosis, RIPK1 signaling, and pyroptosis gene upregulation. **SGC 3027** selectively inhibits the YEATS domain of ENL (**MLLT1**, eleven-nineteen leukemia protein), disrupting super-enhancer-mediated transcription in leukemia. **SGC 0946** potently and selectively inhibits the Tudor domain of **SHPN3**/**PHF20** (PHD finger protein 20, IC50 ~27 nM), blocking H4K20me recognition and implicated in cancer epigenetics. This triplet combination targets distinct reader domains to broadly suppress oncogenic transcription, with potential synergy in hematologic malignancies though untested clinically as a defined regimen.[1][9][11]